| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019865 |
| Receipt No. | R000022947 |
| Official scientific title of the study | A Phase II clinical trial to evaluate the efficacy and safety of intra-arterial infusion chemotherapy for head and neck squamous cell carcinoma |
| Date of disclosure of the study information | 2015/11/20 |
| Last modified on | 2019/03/07 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | A Phase II clinical trial to evaluate the efficacy and safety of intra-arterial infusion chemotherapy for head and neck squamous cell carcinoma | |
| Title of the study (Brief title) | A Phase II clinical trial of intra-arterial infusion chemotherapy for head and neck SCC | |
| Region |
|
|
| Condition | |||
| Condition | head and neck squamous cell carcinoma | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | This study aims to evaluate the efficacy and safety of intra-arterial infusion chemotherapy for head and squamous cell carcinoma. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Adverse event rate from starting treatment till 6months after end of treatment |
| Key secondary outcomes | Response rate |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | We plan intra-arterial administrarion of cisplatinum and docetaxel through the catheter which is put in feeding artery of the cancer.
cisplatinum:40-100mg/m2/weekly docetaxel:5-15mg/m2/weekly administration period:3-6weeks |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients diagnosed with head and neck SCC.
2. ECOG PS of 0-2 3. WBC>3000/ul, Platelet>75000/ul, Creatinine<1.5mg/dL, T-Bil<1.5mg/dL, AST/ALT levels 2.5 times the upper limit of normal 4. Patients agreed this study on document of informed consent. |
|||
| Key exclusion criteria | 1. History of intolerance or hypersensitivity to drugs which will be used or any excipient of the product.
2. Current pregnancy 3. Current known active infection 4. Uncontrolled diabetes 5. Severe heart disease 6. Severe pulmonary disease 7. Patients who are judged to be inappropriate for participation in this study. |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshitaka Okamoto |
| Organization | Graduate School of Medicine, Chiba University |
| Division name | Department of Otorhinolaryngology, Head and Neck Surgery |
| Address | 1-8-1 Inohana, Chuo-ku, Chiba city, Chiba, Japan. |
| TEL | 043-222-7171 |
| yokamoto@faculty.chiba-u.jp | |
| Public contact | |
| Name of contact person | Kazuki Yamasaki |
| Organization | Graduate School of Medicine, Chiba University |
| Division name | Department of Otorhinolaryngology, Head and Neck Surgery |
| Address | 1-8-1 Inohana, Chuo-ku, Chiba city, Chiba, Japan. |
| TEL | 043-222-7171 |
| Homepage URL | |
| k.yamasaki@faculty.chiba-u.jp | |
| Sponsor | |
| Institute | Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Graduate School of Medicine, Chiba University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022947 |